JPWO2018200841A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018200841A5 JPWO2018200841A5 JP2019558417A JP2019558417A JPWO2018200841A5 JP WO2018200841 A5 JPWO2018200841 A5 JP WO2018200841A5 JP 2019558417 A JP2019558417 A JP 2019558417A JP 2019558417 A JP2019558417 A JP 2019558417A JP WO2018200841 A5 JPWO2018200841 A5 JP WO2018200841A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- day
- once
- week
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491803P | 2017-04-28 | 2017-04-28 | |
| US62/491,803 | 2017-04-28 | ||
| PCT/US2018/029607 WO2018200841A1 (en) | 2017-04-28 | 2018-04-26 | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115411A Division JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517704A JP2020517704A (ja) | 2020-06-18 |
| JP2020517704A5 JP2020517704A5 (enExample) | 2020-08-13 |
| JPWO2018200841A5 true JPWO2018200841A5 (enExample) | 2022-06-06 |
Family
ID=63919290
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558417A Withdrawn JP2020517704A (ja) | 2017-04-28 | 2018-04-26 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Pending JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Pending JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11364235B2 (enExample) |
| EP (1) | EP3615047A4 (enExample) |
| JP (3) | JP2020517704A (enExample) |
| CN (1) | CN110612109A (enExample) |
| BR (1) | BR112019022308A2 (enExample) |
| CA (1) | CA3059752A1 (enExample) |
| MX (1) | MX2019012660A (enExample) |
| WO (1) | WO2018200841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3615047A4 (en) * | 2017-04-28 | 2021-01-13 | Actinium Pharmaceuticals, Inc. | METHOD OF TREATMENT OF CANCER WITH A BCL-2 INHIBITOR ASSOCIATED WITH ALPHA-EMISSING RADIOIMMUNOTHERAPY |
| WO2019094931A1 (en) * | 2017-11-10 | 2019-05-16 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| JP2022516170A (ja) * | 2019-01-04 | 2022-02-24 | アクティニウム ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
| BR112022013681A2 (pt) * | 2020-01-10 | 2022-11-16 | Fusion Pharmaceuticals Inc | Imunoterapia sustentada |
| WO2022055842A1 (en) * | 2020-09-08 | 2022-03-17 | Actinium Pharmaceuticals, Inc. | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002211232B2 (en) * | 2000-09-15 | 2006-10-19 | Sloan Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| US8487131B2 (en) * | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| PT3280729T (pt) * | 2015-04-08 | 2022-08-01 | Novartis Ag | Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19 |
| US20180221393A1 (en) * | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
| EP3615047A4 (en) * | 2017-04-28 | 2021-01-13 | Actinium Pharmaceuticals, Inc. | METHOD OF TREATMENT OF CANCER WITH A BCL-2 INHIBITOR ASSOCIATED WITH ALPHA-EMISSING RADIOIMMUNOTHERAPY |
-
2018
- 2018-04-26 EP EP18792272.9A patent/EP3615047A4/en active Pending
- 2018-04-26 CA CA3059752A patent/CA3059752A1/en active Pending
- 2018-04-26 WO PCT/US2018/029607 patent/WO2018200841A1/en not_active Ceased
- 2018-04-26 BR BR112019022308-8A patent/BR112019022308A2/pt unknown
- 2018-04-26 CN CN201880027661.XA patent/CN110612109A/zh active Pending
- 2018-04-26 MX MX2019012660A patent/MX2019012660A/es unknown
- 2018-04-26 US US16/607,168 patent/US11364235B2/en active Active
- 2018-04-26 JP JP2019558417A patent/JP2020517704A/ja not_active Withdrawn
-
2020
- 2020-07-03 JP JP2020115411A patent/JP2020158544A/ja not_active Withdrawn
-
2022
- 2022-05-16 US US17/745,045 patent/US11844799B2/en active Active
-
2023
- 2023-09-28 JP JP2023168404A patent/JP2023165952A/ja active Pending
- 2023-11-02 US US18/500,735 patent/US12133849B2/en active Active
-
2024
- 2024-09-30 US US18/901,169 patent/US20250017919A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020158544A5 (enExample) | ||
| Beutler et al. | The treatment of chronic progressive multiple sclerosis with cladribine. | |
| ES2543383T3 (es) | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| EP2177223A2 (en) | Homoharringonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to sti571 | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| CN104039148A (zh) | 组合als疗法 | |
| JPWO2018200841A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| JP2005525409A5 (enExample) | ||
| JP2024016209A5 (enExample) | ||
| JP2021004249A5 (enExample) | ||
| JPWO2021097220A5 (enExample) | ||
| JPWO2022240688A5 (enExample) | ||
| JPWO2021138264A5 (enExample) | ||
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| JPWO2020146666A5 (enExample) | ||
| JP2006508118A5 (enExample) | ||
| JPWO2022117799A5 (enExample) | ||
| Ito et al. | Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid-dependent nephrotic syndrome | |
| JPWO2023010121A5 (enExample) | ||
| EKINCI et al. | Diazepam as an anti-convulsant agent in ECT | |
| JPWO2022053990A5 (enExample) | ||
| WO2010020789A2 (en) | Medicament and treatment for infections |